RBC Capital downgraded Jasper Therapeutics (JSPR) to Sector Perform from Outperform with a price target of $5, down from $46.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JSPR:
- Jasper Therapeutics downgraded to Market Perform from Outperform at BMO Capital
- Hold Rating for Jasper Therapeutics Amid Uncertainties in Briquilimab’s Clinical Trials and Competitive Challenges
- Cantor cuts Jasper Therapeutics to Neutral after briquilimab update
- Jasper Therapeutics downgraded to Neutral from Overweight at Cantor Fitzgerald
- Buy Rating Maintained for Jasper Therapeutics Amid Manufacturing Setback and Promising Drug Profile